In vivo mapping of amyloid toxicity in Alzheimer disease

G. B. Frisoni, M. Lorenzi, A. Caroli, N. Kemppainen, K. Någren, J. O. Rinne

Research output: Contribution to journalArticlepeer-review


Objective: To study the relationship between gray matter atrophy and amyloid deposition in Alzheimer disease (AD). Methods: Volumetric magnetic resonance (MR) and [C]-PIB PET were acquired from 23 patients with AD and 17 healthy older persons. Standardized [C]-PIB uptake values were coregistered to MR scans in a standard space. Decreased density of and increased [C]-PIB uptake in the gray matter of patients with AD vs controls were assessed with both voxel-based (p <0.05 corrected) and region-of-interest (ROI) analyses. The relationship between decreased density of and increased [C]-PIB uptake in the gray matter was investigated with voxel-based Pearson r maps (thresholded at p <0.05) and ROI linear regression plots. Results: Atrophy mapped to the hippocampus and increased [C]-PIB uptake to large frontal, parietal, and posterior cingulate cortical areas. ROI analysis showed the largest effect size for atrophy in the hippocampus (2.01) and amygdala (1.27) and the highest effect size for [C]-PIB uptake in frontal (2.66), posterior cingulate/retrosplenial (2.43), insular (2.41), and temporal (2.23) regions. In the hippocampus, [C]-PIB uptake was significantly increased, but effect size was milder (1.72). Significant correlations between atrophy and increased [C]-PIB uptake were found in the hippocampal (r = -0.54) and amygdalar ROIs (r = -0.40) but not in the frontal, temporal, posterior cingulate/retrosplenial, insular, and caudate ROIs (r between 0.04 and 0.25). CONCLUSION: The medial temporal lobe might be highly susceptible to amyloid toxicity, whereas neocortical areas might be more resilient.

Original languageEnglish
Pages (from-to)1504-1511
Number of pages8
Issue number17
Publication statusPublished - Apr 28 2009

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'In vivo mapping of amyloid toxicity in Alzheimer disease'. Together they form a unique fingerprint.

Cite this